PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.26%
Negative net income growth while CRWV stands at 7.67%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
142.31%
D&A growth well above CRWV's 26.15%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.41%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
329.41%
Inventory growth of 329.41% while CRWV is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
No Data
No Data available this quarter, please select a different quarter.
-88.92%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
-35.40%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-50.00%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
74.07%
Purchases growth of 74.07% while CRWV is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
48.57%
Less 'other investing' outflow yoy vs. CRWV's 202.79%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
55.42%
We have mild expansions while CRWV is negative at -70.42%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
181.33%
Stock issuance far above CRWV's 4.88%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
4.37%
Buyback growth of 4.37% while CRWV is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.